Variations in genotype-phenotype correlations in phenylketonuria patients

Genetics and Molecular Research

Volumn 9, Issue 1, 2010, Pages 1-8

  Santos, L L ^a,c   Fonseca, C G ^a   Starling, A L P ^a   Januario J N ^a   Aguiar, M J B ^a   Peixoto, M G C D ^b   Carvalho, M R S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b EMBRAPA CERRADOS   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

Correlation; Genotype; Minas Gerais, Brazil; Phenotype; Phenylketonuria

Indexed keywords

PHENYLALANINE;

ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE COURSE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERPHENYLALANINEMIA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEWBORN; NULL ALLELE; PHENYLKETONURIA;

AMINO ACID SEQUENCE; BRAZIL; GENETIC VARIATION; GENOTYPE; HUMANS; INFANT; MUTATION; PHENOTYPE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; SEVERITY OF ILLNESS INDEX;

EID: 77649244529     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol9-1gmr670     Document Type: Article

References (32)

1. Anonymous (2003). PAHdb. Phenylalanine Hydroxylase Locus Knowledgebase. Available at [http://www.pahdb.mcgill.ca/]. Accessed August 4, 2009.
2. Acosta A, Silva W Jr, Carvalho T, Gomes M, et al. (2001). Mutations of the phenylalanine hydroxylase (PAH) gene in Brazilian patients with phenylketonuria. Hum. Mutat. 17: 122-130.
3. Aulehla-Scholz C and Heilbronner H (2003). Mutational spectrum in German patients with phenylalanine hydroxylase deficiency. Hum. Mutat. 21: 399-400.
4. Benit P, Rey F, Blandin-Savoja F, Munnich A, et al. (1999). The mutant genotype is the main determinant of the metabolic phenotype in phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 68: 43-47.
5. Bercovich D, Elimelech A, Zlotogora J, Korem S, et al. (2008). Genotype-phenotype correlations analysis of mutations in the phenylalanine hydroxylase (PAH) gene. J. Hum. Genet. 53: 407-418.
6. Clague A and Thomas A (2002). Neonatal biochemical screening for disease. Clin. Chim. Acta 315: 99-110.
7. Daniele A, Scala I, Cardillo G, Pennino C, et al. (2009). Functional and structural characterization of novel mutations and genotypephenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy. FEBS J. 276: 2048-2059.
8. Dipple KM and McCabe ER (2000). Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am. J. Hum. Genet. 66: 1729-1735.
9. Dipple KM, Phelan JK and McCabe ER (2001). Consequences of complexity within biological networks: robustness and health, or vulnerability and disease. Mol. Genet. Metab. 74: 45-50.
10. Erlandsen H and Stevens RC (1999). The structural basis of phenylketonuria. Mol. Genet. Metab. 68: 103-125.
11. Erlandsen H, Patch MG, Gamez A, Straub M, et al. (2003). Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria. Pediatrics 112: 1557-1565.
12. Guldberg P, Rey F, Zschocke J, Romano V, et al. (1998). A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am. J. Hum. Genet. 63: 71-79.
13. Guttler F (1980). Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. Acta Paediatr. Scand. Suppl 280: 1-80.
14. Guttler F, Azen C, Guldberg P, Romstad A, et al. (1999). Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. Pediatrics 104: 258-262.
15. Jennings IG, Cotton RG and Kobe B (2000). Structural interpretation of mutations in phenylalanine hydroxylase protein aids in identifying genotype-phenotype correlations in phenylketonuria. Eur. J. Hum. Genet. 8: 683-696.
16. Kasnauskiene J, Cimbalistiene L and Kucinskas V (2003). Validation of PAH genotype-based predictions of metabolic phenylalanine hydroxylase deficiency phenotype: investigation of PKU/MHP patients from Lithuania. Med. Sci. Monit. 9: CR142-CR146.
17. Kayaalp E, Treacy E, Waters PJ, Byck S, et al. (1997). Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am. J. Hum. Genet. 61: 1309-1317.
18. Kim SW, Jung J, Oh HJ, Kim J, et al. (2006). Structural and functional analyses of mutations of the human phenylalanine hydroxylase gene. Clin. Chim. Acta 365: 279-287.
19. Leandro J, Nascimento C, de Almeida IT and Leandro P (2006). Co-expression of different subunits of human phenyl- phenylalanine hydroxylase: evidence of negative interallelic complementation. Biochim. Biophys. Acta 1762: 544-550.
20. Mallolas J, Mila M, Lambruschini N, Cambra FJ, et al. (1999). Biochemical phenotype and its relationship with genotype in hyperphenylalaninemia heterozygotes. Mol. Genet. Metab. 67: 156-161.
21. O'Flynn ME, Holtzman NA, Blaskovics M, Azen C, et al. (1980). The diagnosis of phenylketonuria: a report from the Collaborative Study of Children Treated for Phenylketonuria. Am. J. Dis. Child 134: 769-774.
22. Pey AL, Desviat LR, Gamez A, Ugarte M, et al. (2003). Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum. Mutat. 21: 370-378.
23. Rivera I, Cabral A, Almeida M, Leandro P, et al. (2000). The correlation of genotype and phenotype in Portuguese hyperphenylalaninemic patients. Mol. Genet. Metab. 69: 195-203.
24. Santos LL, Magalhaes MC, Reis AO, Starling AL, et al. (2006). Frequencies of phenylalanine hydroxylase mutations I65T, R252W, R261Q, R261X, IVS10nt11, V388M, R408W, Y414C, and IVS12nt1 in Minas Gerais, Brazil. Genet. Mol. Res. 5: 16-23.
25. Santos LL, Castro-Magalhaes M, Fonseca CG, Starling AL, et al. (2008). PKU in Minas Gerais State, Brazil: mutation analysis. Ann. Hum. Genet. 72: 774-779.
26. SAS Institute (2003). SAS/STAT® Software: Changes and Enhacements through Release 9.1. SAS Institute, Cary. Scriver CR (2002). Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics. J. Pediatr. 140: 502-506.
27. Scriver CR (2007). The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 28: 831-845.
28. Scriver CR and Waters PJ (1999). Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 15: 267-272.
29. Scriver CR and Kaufman S (2001). The Hyperphenylalaninemias. In: The Metabolic and Molecular Bases of Inherited Disease (Scriver CR, Beaudet AL, Sly WS and Valle D, eds.). McGraw-Hill, New York, 1667-1724.
30. Waters PJ (2003). How PAH gene mutations cause hyper-phenylalaninemia and why mechanism matters: insights from in vitro expression. Hum. Mutat. 21: 357-369.
31. Waters PJ, Parniak MA, Nowacki P and Scriver CR (1998). In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function. Hum. Mutat. 11: 4-17.
32. Zschocke J (2003). Phenylketonuria mutations in Europe. Hum. Mutat. 21: 345-356.